IMI2 (The Innovative Medicines Initiative) 15th call 2018


Announcement "closed"
Organization:
European Commission
Scope:
International
Start:
Internal deadline:
Official deadline:
Description:

Objectiu de la convocatòria


IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA).


The goal of the Innovative Medicines Initiative 2 (IMI 2) is to develop next generation vaccines, medicines and treatments, such as new antibiotics. It will build on the successes and lessons learnt under IMI. Like IMI, it will bring together companies, universities, public laboratories, innovative small and medium-sized enterprises (SMEs), patient groups and regulators in collaborative projects that will pave the way for breakthrough vaccines, medicines and treatments to tackle Europe's growing health challenges, and secure the future international competitiveness of Europe's pharmaceutical industry.

 

Característiques principals


This Call is being run in a two stage submission and evaluation process.
Deadline 1st stage: 24 october 2018Deadline 2nd stage: 15 May 2019
Característiques principals

Topics of the 15th Call:

  • Topic 1: Integrated research platforms enabling patient-centric drug development
  • Topic 2: Blockchain Enabled Healthcare
  • Topic 3: Microenvironment imposed signatures in tissue and liquid biopsies in immune-mediated diseases
  • Topic 4: Emerging translational safety technologies and tools for interrogating human immuno-biology
  • Topic 5: Development and validation of translational platforms in support of synaptopathy drug discovery
  • Topic 6: Digital endpoints in neurodegenerative and immune-mediated diseases

Topics under the IMI2 Antimicrobial Resistance (AMR) Accelerator programme:

Topic 7: AMR Accelerator programme Pillar A: Capability Building Network to accelerate and validate scientific discoveries

Topic 8: AMR Accelerator programme Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic.

 

Convocatòria (URL)

https://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/calls/h2020-jti-imi2-2018-15-two-stage.html

 

Dotació
IMI JU collaborative projects are implemented through a co-financing scheme. The IMI JU grants financial support to the eligible entities, while the other entities (including the EFPIA companies) participate in the project with their own resources.